Quantcast

Latest Medical statistics Stories

2014-03-18 23:26:23

Launch of ADDPLAN® 6.1 to Expedite and Improve Decision-Making in Clinical Trials Reston, Virginia (PRWEB) March 18, 2014 Aptiv Solutions, a global biopharmaceutical and medical device development services company leading the design and implementation of innovative approaches that improve data quality, efficiency, and productivity of product development, today announced the release of ADDPLAN® 6.1, the first statistical software to enable the use of surrogate endpoints to...

2014-03-13 23:27:22

JDP Therapeutics Inc., a privately held specialty pharmaceutical company, is pleased to announce that the Company’s Investigational New Drug (IND) to conduct an initial Phase 3 clinical trial of JDP-205 in patients with acute urticaria associated with an acute allergic reaction has been cleared by the U.S. Food and Drug Administration (FDA). Blue Bell, PA (PRWEB) March 13, 2014 JDP Therapeutics Inc., a privately held specialty pharmaceutical company, is pleased to announce that the...

2014-03-13 08:28:16

Achieved Negative Predictive Value and Sensitivity ~97% and Specificity ~38% CASTLE ROCK, Colo., March 13, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced positive top-line results from its pivotal U.S. study. The APPY1 Test performed well,...

2014-03-12 23:30:50

Salus IRB maintains a legacy of 28 years of continuous service coupled with expanded capabilities. Austin, Texas (PRWEB) March 12, 2014 RCRC IRB announced today that its organization has changed its name to Salus IRB. The management, administrative staff, ownership structure, and review board memberships remain unchanged. “Clinical trials are more complicated, costly, and fast-paced than ever before,” says Salus President Dwight DuBois. “Salus recognizes this changing scientific...

2014-03-11 16:26:27

Conference call to be held on Tuesday, March 11, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, March 11, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and anticipated near-term milestones and announced fourth quarter and year end 2013 financial results. Clinical Developments and Anticipated Near-term Milestones -- Custirsen -- The SYNERGY Phase 3 trial is designed to...

2014-03-11 08:29:47

SAN DIEGO, March 11, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today that the United States Adopted Names (USAN) Council has selected "vepoloxamer" as the unique non-proprietary (generic) name for the active pharmaceutical ingredient (API) in MST-188, the Company's lead product candidate. Mast sought a unique name for its API to clearly identify it as different from non-purified poloxamers. In support of its application, the Company argued that drug...

2014-03-06 23:31:26

Connance Enhancements Meet the Growing Financial Challenges of Providers and Managing Patient Relationships Waltham, MA (PRWEB) March 06, 2014 Connance, Inc. (http://www.connance.com), a leading provider of innovative, predictive analytic-based programs that improve financial performance of healthcare enterprises, today announced the expansion of its patient-pay solution including new predictive analytics, expanded platform reporting and additional consumer engagement functionality. Since...

2014-03-04 08:32:44

CLEVELAND, March 4, 2014 /PRNewswire/ -- Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, today announced that it has entered into clinical trial agreements with four of the top ranked rehabilitation institutions in the United States to support the testing and development of the Indego(®) exoskeleton. Parker is currently developing a second generation device for clinical trials starting in July 2014 to support submission for FDA approval....

2014-02-27 16:27:29

Experienced leaders form Provision Research Compliance Services, a joint venture between Schulman Associates IRB, Inc. and Falcon Consulting Group, LLC CINCINNATI and PHILADELPHIA, Feb. 27, 2014 /PRNewswire/ -- Schulman Associates IRB, Inc. and Falcon Consulting Group, LLC announced today that they have formed a joint venture, Provision Research Compliance Services. Provision offers global consultancy services for the development and implementation of Good Clinical Practice (GCP) and...

2014-02-26 08:30:01

ROTTERDAM, Netherlands and BOSTON, Feb. 26, 2014 /PRNewswire/ -- Speed, efficiency and accuracy are vital to the success of clinical trials. With large amounts of data collected and significant room for data submission errors, there is even greater potential to disqualify participating patients or expose subjects to unnecessary risky procedures due to data errors. To address these needs in clinical trials, Cardialysis, an independent Clinical Research Organization (CRO), has...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related